Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Monograph from the Acute Leukemia Forum 1999 on Advances and Controversies in the Therapy of Acute Myelogenous Leukemia
  • Published:

Treatment of relapsed and refractory acute myelogenous leukemia

Leukemia volume 14, pages 476–479 (2000)Cite this article

Abstract

Evidence suggests that the salvage therapy utilized for relapsed and refractory acute myelogenous leukemia (AML) should differ based on the duration of a patient's complete remission (CR), the principal predictor of outcome. While standard regimens have produced higher CR rates than investigational regimens, these rates have not translated into improved survival in patients with initial remission durations of <1 year. Accordingly, there is no need to give standard regimens to these patients who rather should receive investigational therapy once relapse is discovered. In contrast, in patients with initial remission durations of 1–2 years, standard regimens do increase survival compared to investigational regimens. A somewhat artificial distinction has been placed between phase i and phase ii studies. The agents to be studied in phase ii trials are many, but the patients are limited, so we need to be more innovative in our trial designs. One such proposal, utilizing a bayesian selection design which calls for randomizing a small number of patients among several investigational treatments, will be discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T . Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy Leukemia 1990 4: 184–188

    CAS  PubMed  Google Scholar 

  2. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M . A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia Blood 1996 88: 756

    CAS  PubMed  Google Scholar 

  3. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E III . The effect of chemotherapy on acute leukemia in the human J Chron Dis 1961 14: 593

    Article  CAS  Google Scholar 

  4. Estey E, Shen Y, Thall PF . Effect of time to achieve CR on subsequent survival time and disease-free survival time in patients with AML, RAEB-t, or RAEB in whom response is established after the first course of chemotherapy Blood (in press)

  5. Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E . Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy Blood 1999 93: 3149–3150

    CAS  PubMed  Google Scholar 

  6. O'Quigley J, Pepe M, Fisher L . Continual reassessment method: a practical design for phase I clinical trials in cancer Biometrics 1990 46: 33–48

    Article  CAS  Google Scholar 

  7. Goodman SN, Zahurak ML, Piantadosi S . Some practical improvements in the continual reassessment method for phase I studies Stat Med 1995 14: 1149–1161

    Article  CAS  Google Scholar 

  8. Thall PF, Russell KE . A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials Biometrics 1998 54: 251–264

    Article  CAS  Google Scholar 

  9. Thall PF, Estey EH, Sung His-Guang . A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials Invest New Drugs (in press)

  10. Thall PF, Simon RM, Estey EH . Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes Stat Med 1995 14: 357–379

    Article  CAS  Google Scholar 

  11. Thall PF, Sung HG . Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials Stat Med 1998 17: 1563–1580

    Article  CAS  Google Scholar 

  12. Thall PF, Estey EH . A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation Stat Med 1993 12: 1197–1211

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX 77030, USA

    EH Estey

Authors
  1. EH Estey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Estey, E. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14, 476–479 (2000). https://doi.org/10.1038/sj.leu.2401568

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401568

Keywords

This article is cited by

Search

Advanced search

Quick links